Advertisement

Clinical Pharmacokinetics

, Volume 33, Issue 1, pp 18–31 | Cite as

The Role of β-Glucuronidase in Drug Disposition and Drug Targeting in Humans

  • Bernhard Sperker
  • Janne T. Backman
  • Heyo K. KroemerEmail author
Review Article Drug Disposition

Summary

Glucuronides of drugs often accumulate during long term therapy. The hydrolysis of glucuronides can be catalysed by β-glucuronidase, an enzyme expressed in many tissues and body fluids in humans. The possible contribution of β-glucuronidase to drug disposition in humans has not been assessed in a systematic manner, but this enzyme may be able to release, locally or systemically, the active or inactive parent compound from drug glucuronides, thereby modifying the disposition and action of these drugs.

Based on the information available on the localisation, expression and variability of β-glucuronidase, the concept of β-glucuronidase-mediated drug metabolism is outlined in this article using examples from the literature. Since some issues surrounding the β-glucuronidase-mediated deconjugation of drug glucuronides still need to be clarified in humans, additional data from animal models supporting this concept have been included. Moreover, as β-glucuronidase has already been proven to be useful in tumour specific bioactivation of glucuronide prodrugs of anticancer agents, we also focus on anticancer prodrug approaches utilising β-glucuronidase. This review summarises the role of β-glucuronidase in drug disposition and drug targeting in humans.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kroemer HK, Klotz U. Glucuronidation of drugs: a re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 1992; 23(4): 292–310PubMedGoogle Scholar
  2. 2.
    Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51: 347–69PubMedGoogle Scholar
  3. 3.
    Osborne RJ, Joel SP, Slevin ML. Analgesic activity of morphine-6-glucuronide. Lancet 1988; I: 828Google Scholar
  4. 4.
    Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34: 130–8PubMedGoogle Scholar
  5. 5.
    Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145–7PubMedGoogle Scholar
  6. 6.
    Sisenwine SF, Tio CO, Hadley FV, et al. Species related differences in the stereoselective glucuronidation of oxazepam. Drug Metab Dispos 1982; 10: 605–8PubMedGoogle Scholar
  7. 7.
    Sutfin TA, Perini GI, Molnar G, et al. Multiple-dose pharmacokinetics of impramine and its major active and conjugated metabolites in depressed patients. J Clin Psychopharmacol 1988; 8(1): 48–53PubMedGoogle Scholar
  8. 8.
    Walle T, Conradi EC, Walle UK, et al. Propranolol glucuronide accumulation during long-term therapy: a proposed storage mechanism for propranolol. Clin Pharmacol Ther 1979; 26: 686–95PubMedGoogle Scholar
  9. 9.
    Eriksson L-O, Wählin-Boll E, Odar-Cederlöf I, et al. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal. Eur J Clin Pharmacol 1989; 36: 165–74Google Scholar
  10. 10.
    Fromm MF, Botsch S, Heinkele G, et al. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites. Eur J Clin Pharmacol 1995; 48: 279–83PubMedGoogle Scholar
  11. 11.
    Lieberman JA, Cooper TB, Suckow RF, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985; 37(3): 301–7PubMedGoogle Scholar
  12. 12.
    Hasselström J, Berg U, Löfgren A, et al. Long lasting respiratory depression induced by morphine-6-glucuronide. Br J Clin Pharmacol 1989; 27: 515–8PubMedGoogle Scholar
  13. 13.
    Meffin PJ, Zilm DM, Veenendaal JR. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle. J Pharmacol Exp Ther 1983; 227(3): 732–8PubMedGoogle Scholar
  14. 14.
    Brater DC. Clinical pharmacology of NSAIDs. J Clin Pharmacol 1988; 28: 518–23PubMedGoogle Scholar
  15. 15.
    Brunelle FM, Verbeeck RK. Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica 1996; 26(2): 123–31PubMedGoogle Scholar
  16. 16.
    Wakabayashi M. Beta-glucuronidases in metabolic hydrolysis. In: Fishman WH, editor. Metabolic conjugation and metabolic hydrolysis. New York: Academic Press, 1970: 519–602Google Scholar
  17. 17.
    Paigen K. Mammalian β-glucuronidase: genetics, molecular biology and cell biology. Prog Nucleic Acid Res Mol Biol 1989; 37: 155–205PubMedGoogle Scholar
  18. 18.
    Bosslet K, Czech J, Hoffmann D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994; 54: 2151–9PubMedGoogle Scholar
  19. 19.
    Henle KJ, Monson TP, Nagle WA, et al. Tumor-targeted cell killing with 8-hydroxyquinolyl-glucuronide. Radiat Res 1988; 115(2): 373–86PubMedGoogle Scholar
  20. 20.
    Houba PHJ, Leenders RGG, Boven E, et al. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy. Biochem Pharmacol 1996; 52(3): 455–63PubMedGoogle Scholar
  21. 21.
    Sinhababu AK, Thakker DR. Prodrugs of anticancer agents. Adv Drug Deliv Rev 1996; 19: 241–73Google Scholar
  22. 22.
    Eisenberg Jr F. The mechanism of action of beta-glucuronidase. Fed Proc Fed Am Soc Exp Biol 1959; 18: 221Google Scholar
  23. 23.
    Corrales-Hernandez JJ, Gonzalez-Buitrago JM, Pastor-Encinas I, et al. Androgen environment and beta-glucuronidase activity in the human kidney. Arch Androl 1988; 20(3): 185–91PubMedGoogle Scholar
  24. 24.
    Fishman WH, Kato K, Anstiss CL, et al. Human serum β-glucuronidase; its measurement and some of its properties. Clin Chim Acta 1967; 15: 435–47PubMedGoogle Scholar
  25. 25.
    Sperker B, Mürdter TE, Schick M, et al. Interindividual variability in expression and activity of human β-glucuronidase in liver and kidney: consequences for drug metabolism. J Pharmacol Exp Ther 1997; 281: 914–20PubMedGoogle Scholar
  26. 26.
    Boyer MJ, Tannock IF. Lysosomes, lysosomal enzymes and cancer. Adv Cancer Res 1993; 60: 269–91PubMedGoogle Scholar
  27. 27.
    Stephens RW, Ghosh P, Taylor TK, et al. The origins and relative distribution of polysaccharidases in rheumatoid and osteoarthritic fluids. J Rheumatol 1975; 2: 393–400PubMedGoogle Scholar
  28. 28.
    Camisa C, Hessel A, Rossana C, et al. Autosomal dominant keratoderma, ichthyosiform dermatosis and elevated serum beta-glucuronidase. Dermatologica 1988; 177(6): 341–7PubMedGoogle Scholar
  29. 29.
    Ohta H, Ono M, Sekiya C, et al. Serum immunoreactive β-glucuronidase determined by an enzyme-linked immunosorbent assay in patients with hepatic diseases. Clin Chim Acta 1992; 208(1-2): 9–21PubMedGoogle Scholar
  30. 30.
    Saha AK, Glew RH, Kotier DP, et al. Elevated serum β-glucuronidase activity in acquired immunodeficiency syndrome. Clin Chim Acta 1991; 199(3): 311–6PubMedGoogle Scholar
  31. 31.
    Sly WS, Quinton BA, McAlister WH, et al. Beta glucuronidase deficiency: report of clinical, radiologic and biochemical features of a new mucopolysaccharidosis. J Pediatr 1973; 82(2): 249–57PubMedGoogle Scholar
  32. 32.
    Vervoort R, Islam MR, Sly WS, et al. Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII. Am J Hum Genet 1996; 58(3): 457–71PubMedGoogle Scholar
  33. 33.
    Vervoort R, Lissens W, Liebaers I. Molecular analysis of a patient with hydrops-fetalis caused by beta-glucuronidase deficiency, and evidence for additional pseudogenes. Hum Mutat 1993; 2(6): 443–5PubMedGoogle Scholar
  34. 34.
    Shipley JM, Klinkenberg M, Wu BM, et al. Mutational analysis of a patient with mucopolysaccharidosis type VII, and identification of pseudogenes. Am J Hum Genet 1993; 52: 517–26PubMedGoogle Scholar
  35. 35.
    Vervoort R, Islam MR, Sly W, et al. A pseudodeficiency allele (d152n) of the human beta-glucuronidase gene. Am J Hum Genet 1995; 57(4): 798–804PubMedGoogle Scholar
  36. 36.
    Miller RD, Hoffmann JW, Powell PP, et al. Cloning and characterization of the human beta-glucuronidase gene. Genomics 1990; 7(2): 280–3PubMedGoogle Scholar
  37. 37.
    Speleman F, Vervoort R, Vanroy N, et al. Localization by fluorescence in situ hybridization of the human functional beta-glucuronidase gene (GUSB) to 7q11.21q11.22 and two pseudogenes to 5p13 and 5q13. Cytogenet Cell Genet 1996; 72(1): 53–5PubMedGoogle Scholar
  38. 38.
    Shipley JM, Miller RD, Wu BM, et al. Analysis of the 5′ flanking region of the human beta-glucuronidase gene. Genomics 1991; 10(4): 1009–18PubMedGoogle Scholar
  39. 39.
    Oshima A, Kyle JW, Miller RD, et al. Cloning, sequencing, and expression of cDNA for human beta-glucuronidase. Proc Natl Acad Sci USA 1987; 84(3): 685–9PubMedGoogle Scholar
  40. 40.
    Brot FE, Bell CE, Sly WS. Purification and properties of beta-glucuronidase from human placenta. Biochemistry 1978; 17(3): 385–91PubMedGoogle Scholar
  41. 41.
    Gehrmann MC, Opper M, Sedlacek HH, et al. Biochemical properties of recombinant human β-glucuronidase synthesized in baby hamster kidney cells. Biochem J 1994; 301: 821–8PubMedGoogle Scholar
  42. 42.
    Islam MR, Grubb JH, Sly WS. C-terminal processing of human beta-glucuronidase: the propeptide is required for full expression of catalytic activity, intracellular retention, and proper phosphorylation. J Biol Chem 1993; 268(30): 22627–33PubMedGoogle Scholar
  43. 43.
    Jain S, Drendel WB, Chen ZW, et al. Structure of human beta-glucuronidase reveals candidate lysosomal targeting and active-site motifs. Nature Structure Biol 1996; 3(4): 375–81Google Scholar
  44. 44.
    Tanaka J, Gasa S, Sakurada K, et al. Characterization of the subunits and sugar moiety of human placental and leukemic beta-glucuronidase. Biol Chem Hoppe Seyler 1992; 373(1): 57–62PubMedGoogle Scholar
  45. 45.
    Brown J, Novak EK, Takeuchi K, et al. Lumenal location of the microsomal beta-glucuronidase-egasyn complex. J Cell Biol 1987; 105(4): 1571–8PubMedGoogle Scholar
  46. 46.
    Medda S, Stevens AM, Swank RT. Involvement of the esterase active site of egasyn in compartmentalization of beta-glucuronidase within the endoplasmic reticulum. Cell 1987; 50(2): 301–10PubMedGoogle Scholar
  47. 47.
    Zhen LD, Baumann H, Novak EK, et al. The signal for retention of the egasyn-glucuronidase complex within the endoplasmic reticulum. Arch Biochem Biophys 1993; 304(2): 402–14PubMedGoogle Scholar
  48. 48.
    De Duve C, Pressman C, Gianetto R, et al. Tissue franctionation studies: intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 1955; 60: 604–17Google Scholar
  49. 49.
    Fishman WH, Goldman SS, DeLellis R. Dual localization of β-glucuronidase in endoplasmic reticulum and in lysosomes. Nature 1967; 213: 457–60PubMedGoogle Scholar
  50. 50.
    Tomino S, Paigen K. Egasyn, a protein complexed with microsomal β-glucuronidase. J Biol Chem 1975; 250(3): 1146–8Google Scholar
  51. 51.
    Catterall JF, Leary SL. Detection of early changes in androgen-induced mouse renal beta-glucuronidase messenger ribonucleic acid using cloned complementary deoxyribonucleic acid. Biochemistry 1983; 22(26): 6049–53PubMedGoogle Scholar
  52. 52.
    Palmer R, Gallagher PM, Boyko WL, et al. Genetic control of levels of murine kidney glucuronidase mRNA in response to androgen. Proc Natl Acad Sci USA 1983; 80: 7596–600PubMedGoogle Scholar
  53. 53.
    Bracey LT, Paigen K. Changes in translational yield regulate tissue-specific expression of beta-glucuronidase. Proc Natl Acad Sci USA 1987; 84(24): 9020–4PubMedGoogle Scholar
  54. 54.
    Sokolove PM, Wilcox MA, Thurman RG, et al. Stimulation of hepatic microsomal β-glucuronidase by calcium. Biochem Biophys Res Commun 1984; 121(3): 987–93PubMedGoogle Scholar
  55. 55.
    Schöllhammer I, Poll DS, Bickel MH. Liver microsomal beta-glucuronidase and UDP-glucuronosyltransferase. Enzyme 1975; 20: 269–76PubMedGoogle Scholar
  56. 56.
    Szasz G. Die Bestimmung der β-Glucuronidase Aktivität im Serum mit p-Nitrophenyl-glucuronid. Clin Chim Acta 1967; 15: 275–82Google Scholar
  57. 57.
    Lusis AJ, Tomino S, Paigen K. Isolation, characterization, and radioimmunoassay of murine egasyn, a protein stabilizing glucuronidase membrane binding. J Biol Chem 1976; 251(24): 7753–60PubMedGoogle Scholar
  58. 58.
    Sperker B, Schick M, Kroemer HK. High-performance liquid Chromatographie quantification of 4-methylumbelliferyl-β-D-glucuronide as a probe for human β-glucuronidase activity in tissue homogenates. J Chromatogr B 1996; 685: 181–4Google Scholar
  59. 59.
    Fishman WH, Baker JR. Cellular localization of β-glucuronidase in benign and malignant tissue. J Histochem Cytochem 1956; 4: 412–4Google Scholar
  60. 60.
    Hayashi M, Nakajima Y, Fishman WH. The cytologie demonstration of β-glucuronidase employing naphtol AS-BI glucuronide and hexazonium pararosanilin; a preliminary report. J Histochem Cytochem 1964; 12: 293–7PubMedGoogle Scholar
  61. 61.
    Jefferson RA. Assaying chimeric genes in plants: the GUS gene fusion protein. Plant Mol Biol Reporter 1987; 5(4): 387–405Google Scholar
  62. 62.
    Sperker B, Mürdter TE, Fritz P, et al. ‘Phase III’-drug metabolism in man: characterization of enzyme-substrate interactions of human-glucuronidase [abstract]. Exp Toxicol Pathol 1996; 48(5): 392Google Scholar
  63. 63.
    Brown RT, Carter NE, Scheinmann F, et al. Synthesis of morphine-6-glucuronide via a highly selective enzyme catalysed hydrolysis reaction. Tetrahedron Lett 1995; 36(7): 1117–20Google Scholar
  64. 64.
    Dickinson RG, King AR. Studies on the reactivity of aycl glucuronides. V. Glucuronide-derived covalent binding of diflunisal to bladder tissue of rats and its modulation by urinary pH and β-glucuronidase. Biochem Pharmacol 1993; 46(7): 1175–82PubMedGoogle Scholar
  65. 65.
    Narita M, Nagai E, Hagiwara H, et al. Inhibition of beta-glucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38(7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 1993; 23(1): 5–10PubMedGoogle Scholar
  66. 66.
    Gesson J-P, Jacquesy J-C, Mondon M, et al. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anticancer Drug Des 1994; 9: 409–23PubMedGoogle Scholar
  67. 67.
    Haisma HJ, Boven E, van Muijen M, et al. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Br J Cancer 1992; 66(3): 474–8PubMedGoogle Scholar
  68. 68.
    Azoulay M, Florent JC, Monneret C, et al. Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Anti-cancer Drug Des 1995; 10: 441–50Google Scholar
  69. 69.
    Kauffman FC. Regulation of drug conjugate production by futile cycling in intact cells. In: Kauffman FC, editor. Conjugation-deconjugation reactions in drug metabolism and toxicity. New York: Springer, 1994: 245–55Google Scholar
  70. 70.
    Hansel SB, Morris ME. Hepatic conjugation/deconjugation cycling pathways. Computer simulations examining the effect of Michaelis-Menten parameters, enzyme distribution patterns, and a diffusional barrier on metabolite disposition. J Pharmacokinet Biopharm 1996; 24(2): 219–43PubMedGoogle Scholar
  71. 71.
    Arnoux B, Joseph M, Simoes MH, et al. Antigenic release of paf-acether and β-glucuronidase from alveolar macrophages of asthmatics. Bull Eur Physiopathol Respir 1987; 23: 119–24PubMedGoogle Scholar
  72. 72.
    Ho KJ, Hsu SC, Chen JS, et al. Human biliary beta-glucuronidase: correlation of its activity with deconjugation of bilirubin in the bile. Eur J Clin Invest 1986; 16(5): 361–7PubMedGoogle Scholar
  73. 73.
    Whiting JF, Narciso JP, Chapman V, et al. Deconjugation of bilirubin-IX glucuronides: a physiologic role of hepatic microsomal-glucuronidase. J Biol Chem 1993; 268(31): 23197–201PubMedGoogle Scholar
  74. 74.
    Sirota L, Ferrera M, Lerer N, et al. Beta glucuronidase and hyperbilirubinaemia in breast fed infants of diabetic mothers. Arch Dis Child 1992; 67(1): 120–1PubMedGoogle Scholar
  75. 75.
    Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clin Pharmacokinet 1979; 4: 368–79PubMedGoogle Scholar
  76. 76.
    Caldwell JH, Greenberger NJ. Interruption of the enterohepatic circulation of digitoxin by cholestyramine. J Clin Invest 1971; 50: 2626–37PubMedGoogle Scholar
  77. 77.
    Herman RJ, van Pham JD, Szakacs CBN. Disposition of lorazepam in human beings: enterohepatic recirculation and first-pass effect. Clin Pharmacol Ther 1989; 46: 18–25PubMedGoogle Scholar
  78. 78.
    Plaa GL. The enterohepatic circulation. In: Gillette JR, Mitchell JR, editors. Handbook of experimental pharmacology (28 Pt 3). New York: Springer, 1975: 130–49Google Scholar
  79. 79.
    Marselos M, Dutton G, Hänninen O. Evidence that D-glucaro-1,4-lactone shortens the pharmacological action of drugs being disposed via the bile as glucuronides. Biochem Pharmacol 1975; 24: 1855–8PubMedGoogle Scholar
  80. 80.
    Gugler R, Kürten JW, Jensen CJ, et al. Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol 1979; 15: 341–7PubMedGoogle Scholar
  81. 81.
    Rowe BJ, Meffin PJ. Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle. J Pharmacol Exp Ther 1984; 230(1): 237–41PubMedGoogle Scholar
  82. 82.
    Smith PC, McDonagh AF, Benet LZ. Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig. J Pharmacol Exp Ther 1990; 252(1): 218–24PubMedGoogle Scholar
  83. 83.
    Brunelle FM, Verbeeck RK. Glucuronidation of diflunisal by rat liver microsomes: effect of microsomal β-glucuronidase activity. Biochem Pharmacol 1993; 46(11): 1953–8PubMedGoogle Scholar
  84. 84.
    Abe N, Ebina T, Ishida N. Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice. Microbiol Immunol 1982; 26(6): 535–9PubMedGoogle Scholar
  85. 85.
    Kumagai A, Yano M, Otomo M, et al. Study on the corticoid-like action of glycyrrhizin and mechanism of its action. Endocrinol Jpn 1957; 4: 17–27PubMedGoogle Scholar
  86. 86.
    Pompei R, Flore O, Marccialis MA, et al. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature 1979; 281: 689–90PubMedGoogle Scholar
  87. 87.
    Farese Jr RV, Biglieri EG, Shackleton CHL, et al. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1223–7PubMedGoogle Scholar
  88. 88.
    Akao T, Akao T, Hattori M, et al. Hydrolysis of glycyrrhizin to 18 beta-glycyrrhetyl monoglucuronide by lysosomal beta-D-glucuronidase of animal livers. Biochem Pharmacol 1991; 41(6-7): 1025–9PubMedGoogle Scholar
  89. 89.
    Kanaoka M, Yano S, Kato H, et al. Synthesis and separation of 18-glycyrrhetyl monoglucuronide from serum of a patient with glycyrrhizin-induced pseudo-aldosteronism. Chem Pharm Bull 1986; 34(12): 4978–83PubMedGoogle Scholar
  90. 90.
    Takasuna K, Kasai Y, Kitano Y, et al. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotectan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 1995; 86: 978–84PubMedGoogle Scholar
  91. 91.
    Kari FW, Kauffman FC, Thurman RG. Effect of bile salts on rates of formation, accumulation, and export of mutagenic metabolites from benzo(a)pyrene produced by the perfused rat liver. Cancer Res 1985; 45: 1621–7PubMedGoogle Scholar
  92. 92.
    Whittaker M, Sokolove PM, Thurman RG, et al. Stimulation of 3-benzo[a]pyrenyl glucuronide hydrolysis by calcium activation of microsomal beta-glucuronidase. Cancer Lett 1985; 26: 145–52PubMedGoogle Scholar
  93. 93.
    Kinoshita N, Gelboin HV. Beta-glucuronidase catalyzed hydrolysis of benzo[a]pyrene-3-glucuronide and binding to DNA. Science 1978; 199: 307–9PubMedGoogle Scholar
  94. 94.
    Walaszek Z. Potential use of D-glucaric acid derivatives in cancer prevention. Cancer Lett 1990; 54(1-2): 1–8PubMedGoogle Scholar
  95. 95.
    Walaszek Z, Hanausek-Walaszek M, Webb TE. Inhibition of 7,12-dimethylbenzynthracene-induced rat mammary tumorigenesis by 2,5-di-O-acetyl-D-glucaro-1,4: 6,3-dilactone, an in vivo beta-glucuronidase inhibitor. Carcinogenesis 1984; 5(6): 767–72PubMedGoogle Scholar
  96. 96.
    Tsuruoka T, Fukuyasu H, Ishii M, et al. Inhibition of mouse tumor metastasis with nojirimycin-related compounds. J Antibiot 1996; 49(2): 155–61PubMedGoogle Scholar
  97. 97.
    Levvy GA. The preparation and properties of beta-glucuronidase. Biochemistry 1952; 52: 464–72Google Scholar
  98. 98.
    Young JC, Kenyon EM, Calabrese EJ. Inhibition of beta-glucuronidase in human urine by ascorbic acid. Hum Exp Toxicol 1990; 9(3): 165–70PubMedGoogle Scholar
  99. 99.
    Schmeda-Hirschmann G, Loyola JI, Reyes S, et al. β-Glucuronidase inhibition and diuretic activity of Fabiana imbricata r & p (solanaceae). Phytother Res 1994; 8(8): 485–7Google Scholar
  100. 100.
    Chang HW, Friedman ME, Hileman DL, et al. Inhibition of human synovial beta-glucuronidase by steroidal compounds [short communication]. J Enzym Inhib 1993; 6(4): 331–5Google Scholar
  101. 101.
    Satoh T, Nishimura Y, Kondo S, et al. Synthesis and antimetastatic activity of 6-trichloroacetamido and 6-guanidino analogues of siastatin B. J Antibiot 1996; 49(3): 321–5PubMedGoogle Scholar
  102. 102.
    Igarashi Y, Ichikawa M, Ichikawa Y. Synthesis of a potent inhibitor of beta-glucuronidase. Tetrahedron Lett 1996; 37(16): 2707–8Google Scholar
  103. 103.
    Nishimura Y, Satoh T, Adachi H, et al. The first L-iduronic acid-type 1-N-iminosugars having inhibitory activity of experimental metastasis. J Am Chem Soc 1996; 118(12): 3051–2Google Scholar
  104. 104.
    Melton RG, Sherwood R. Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 1996; 88(3/4): 153–65PubMedGoogle Scholar
  105. 105.
    Blakey DC, Burke PJ, Davies DH, et al. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease. Ther Monoclonals 1995; 23: 1047–50Google Scholar
  106. 106.
    Bagshawe KD, Springer CJ, Searle F, et al. A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 1988; 58: 700–3PubMedGoogle Scholar
  107. 107.
    Bagshawe KD. Antibody-directed enzyme prodrug therapy. Clin Pharmacokinet 1994; 27: 368–76PubMedGoogle Scholar
  108. 108.
    Sharma SK, Bagshawe KD, Melton RG, et al. Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trial. Cell Biophys 1992; 21: 109–20PubMedGoogle Scholar
  109. 109.
    Bosslet K, Czech J, Lorenz P, et al. Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. Br J Cancer 1992; 65(2): 234–8PubMedGoogle Scholar
  110. 110.
    Leenders RGG, Scheeren HW, Houba PHJ, et al. Synthesis and evaluation of novel daunomycin-phosphate-sulfate-beta-glucuronide and beta-glucoside prodrugs for application in ADEPT. Bioorg Med Chem Lett 1995; 5(24): 2975–80Google Scholar
  111. 111.
    Wang SM, Chern JW, Yeh MY, et al. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 1992; 52(16): 4484–91PubMedGoogle Scholar
  112. 112.
    Mürdter TE, Sperker B, Kivisto KT, et al. Enhanced uptake of doxorubicin into bronchial carcinoma: β-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Cancer Res 1997; 57: 2440–5PubMedGoogle Scholar
  113. 113.
    Martin GR, Jain RK. Noninvasive measurement of interstitial pH profiles in normal and neoplastic tissue using fluorescence ratio imaging microscopy. Cancer Res 1994; 54: 5670–4PubMedGoogle Scholar
  114. 114.
    Ashby BS. pH studies in human malignant tumours. Lancet 1966; II: 312–5Google Scholar
  115. 115.
    Jähde E, Rajewsky MF. Tumor-selective modification of cellular microenvironment in vivo: effect of glucose infusion on the pH in normal and malignant rat tissues. Cancer Res 1982; 42: 1505–12PubMedGoogle Scholar
  116. 116.
    Fishman WH, Anlyan AJ. The presence of high β-glucuronidase activity in cancer tissue [letter]. J Biol Chem 1947; 169: 449–50PubMedGoogle Scholar
  117. 117.
    Anghileri LJ, Miller ES. β-glucuronidase activity in tumors. Accumulation of radioiodinated phenolphthalein. Oncology 1971; 25: 19–32PubMedGoogle Scholar
  118. 118.
    Fishman WH, Baker JR, Borges PRF. Localization of β-glucuronidase in some human tumors. Cancer 1959; 12: 240–5PubMedGoogle Scholar
  119. 119.
    Young CW, Yagoda A, Bittar ES, et al. Therapeutic trial of aniline mustard in patients with advanced cancer: comparison of therapeutic response with cytochemical assessment of tumor cell beta-glucuronidase activity. Cancer 1976; 38: 1887–95PubMedGoogle Scholar
  120. 120.
    Connors TA, Whisson ME. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 1966; 210: 866–7PubMedGoogle Scholar
  121. 121.
    Connors TA, Farmer PB, Foster AB, et al. Metabolism of aniline mustard [N,N-di-(2-chloroethyl)aniline]. Biochem Pharmacol 1973; 22: 1971–80PubMedGoogle Scholar
  122. 122.
    Double JA, Workman P. A new high-glucuronidase mouse tumor curable by aniline mustard therapy. Cancer Treat Rep 1977; 61(5): 909–11PubMedGoogle Scholar
  123. 123.
    Bosslet K, Czech J, Hoffmann D. A novel one-step tumor-selective prodrug activation system. Tumor Targeting 1995; 1: 45–50Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Bernhard Sperker
    • 1
  • Janne T. Backman
    • 1
  • Heyo K. Kroemer
    • 1
    Email author
  1. 1.Dr. Margarete Fischer-Bosch-Institut für Klinische PharmakologieStuttgartGermany

Personalised recommendations